:?

Begoña Monge-Maillo1, Rogelio López-Vélez

  • 1National Reference Unit for Tropical Diseases, WHO Collaborating Centre for Clinical Management of Leishmaniasis, Infectious Diseases Department, Ramón y Cajal University Hospital, IRICYS. CIBERINFEC, Madrid, Spain.

概括

移植患者患有内脏莱什曼病,通常与免疫抑制有关,需要更新管理. 新的生物标志物可能有助于监测治疗有效性,并指导这些不断增长的病例中的二次预防.